The Peptide Wars
Approved drugs, grey -market compounds and the strange politics of modern medicine.
Everybody seems to have a peptide now.
The bodybuilder has one for muscle growth.
The wellness influencer has one for longevity.
The anti-aging clinic has one for skin.
The pharmaceutical industry may have discovered a trillion-dollar market in obesity treatment.
And somewhere in the middle sits the ordinary person, trying to work out whether peptides represent the future of medicine or simply the latest chapter in humanity’s endless search for shortcuts.
Most people who use peptides understand that they are short chains of amino acids. That part is not especially mysterious.
What becomes much harder to understand is why those amino acids have been arranged in that particular sequence, what receptors they interact with, which biological signals they amplify, and what unintended consequences may emerge over time.
Knowing that a peptide is “just amino acids” can sometimes create a false sense of simplicity. A key is just metal. A computer chip is just silicon. What matters is not what something is made from, but what it does.
The fact that many important substances in our own bodies are peptides only adds to this sense of familiarity.
Insulin is a peptide.
GLP-1 hormones are peptides.
Oxytocin is a peptide.
Collagen contains peptides.
But “peptides” have become a single label for substances that belong to very different worlds.
Some are approved medicines that have survived years of clinical trials. Some are approved drugs being prescribed off-label. Others remain experimental compounds undergoing legitimate research. And some exist almost entirely in a grey market, sold online as “research chemicals” while being purchased by people who fully intend to take them.
That distinction matters.
The peptide that eventually becomes the next breakthrough treatment for obesity may have very little in common with the peptide somebody buys online to improve recovery, increase tanning or slow aging. Some compounds will eventually become standard medicine. Others will quietly disappear when larger studies fail to show meaningful benefits. Some may prove harmful.
The problem is that we increasingly talk about all of them as though the science has already been settled.
What interests me most, however, is not the chemistry.
It is the culture.
Peptides may be the most scientifically sophisticated substances ever embraced by communities that often distrust scientific institutions.
Many people who express deep scepticism toward pharmaceutical companies, regulators and medical institutions appear remarkably comfortable purchasing laboratory-produced compounds from anonymous suppliers because a podcast host, influencer or online community told them they work.
At first glance, this feels like a contradiction.
But maybe it isn’t.
It’s easy to understand the appeal. Many of these compounds are attractive precisely because conventional medicine often moves slowly. People living with pain, obesity, poor recovery or chronic illness may feel they have little to lose by trying something new.
For some, peptides represent hope. They offer the possibility that solutions may exist outside traditional pathways, particularly when conventional medicine has few answers to offer.
The pandemic years left many people with a deep distrust of institutions. Some who became sceptical of pharmaceutical companies and public health authorities now place their trust elsewhere: in podcasters, online communities, independent researchers and personal experimentation. Whether that shift is wise or not, it represents a profound change in where people seek authority.
Perhaps people have not stopped trusting.
Perhaps they have simply shifted their trust away from traditional institutions and toward alternative sources of information, communities and personal experience.
The same questions people asked during the pandemic still seem reasonable:
What are the long-term effects?
How much data do we have?
What don’t we know yet?
They are also reasonable questions to ask of experimental peptides.
None of this means institutions are always right. Pharmaceutical companies have made mistakes. Regulators have made mistakes. Medicine contains countless examples of experts getting things wrong.
Scepticism is healthy.
Science depends on it.
But scepticism and cynicism are different things.
Scepticism asks for evidence.
Cynicism assumes everybody is lying.
And once cynicism takes hold, expertise itself begins to lose value.
This is where I find myself occupying an increasingly unfashionable position.
I am not anti-peptide.
Quite the opposite.
GLP-1 receptor agonists have already changed medicine. New peptide therapies are being investigated for cancer, metabolic disease, autoimmune disorders and tissue repair. Some of these compounds may become genuine breakthroughs.
Others will not.
The difficulty is knowing which is which.
I am not a chemist.
I am not a pharmacologist.
I cannot evaluate manufacturing standards from a website. I cannot read a molecular structure and understand its long-term implications. I cannot independently assess whether a signalling pathway might have unintended consequences ten years from now.
And because I cannot do those things, I have reached a very simple conclusion.
I wait.
Perhaps that means I miss the next breakthrough. Perhaps somebody else benefits years before I do.
But I also avoid the compounds that fail, the side effects that emerge later, and the risks that nobody fully understood at the beginning.
Take the growing popularity of peptides used for tanning, recovery or anti-aging. Future research may show that some are both safe and effective. Others may fail proper study altogether. One could eventually prove to carry risks we do not yet understand, including effects on cancer growth or other long-term health outcomes.
I genuinely do not know.
And that uncertainty matters.
Your body belongs to you. People should have the freedom to decide what risks they are willing to accept. Some people are comfortable experimenting. Others are not.
Neither position is inherently wrong.
What concerns me is not experimentation itself, but confidence: the certainty with which people discuss compounds they do not truly understand.
Modern culture increasingly rewards confidence over expertise. The loudest voice becomes the authority, and personal experience can begin to outweigh evidence. Confidence itself sometimes becomes a substitute for knowledge.
Meanwhile, the person who says “I don’t know” appears weak.
Yet “I don’t know” may be the most scientifically honest answer available.
The future of peptides will probably resemble the history of medicine itself. Some compounds will become revolutionary treatments. Some will quietly disappear. Some will prove dangerous. Most will turn out to be more complicated than either their supporters or their critics claim.
Perhaps I will miss out on the occasional breakthrough by waiting.
I can live with that.
Because I also avoid gambling with a system I barely understand.
Sometimes the wisest thing we can say about a new technology is not that it works or that it is dangerous.
Sometimes the wisest answer is simply this:
I don't know enough to gamble with my body on it.
Stay Curious. Stay Frosty.